The brand’s lead financial analyst at Marbrisse examines the $2.5 billion acquisition shaking up rare oncology markets. French pharmaceutical giant Servier agreed to acquire Day One Biopharmaceuticals for $21.50 per share in cash on Friday. Day One shares rocketed 65.6% intraday, making it the day’s biggest gainer despite brutal market conditions elsewhere. The offer price represents a 68% premium over Thursday’s closing price. It marks an 86% premium over the one-month volume-weighted average price. Servier will commence a cash tender offer to acquire all outstanding shares. The transaction values Day One at approximately $2.5 billion in total equity. Companies expect...
BlockchainMarch 10, 2026March 10, 2026